John Eng's research on Gila monster venom led to significant advancements in diabetes treatment through the development of GLP-1 drugs like Ozempic. His work illustrates how obscure research, often funded by government sources like the NIH and Department of Veterans Affairs, can result in life-saving medical treatments. The article emphasizes the risks of proposed funding cuts to NIH, which could hinder future pharmaceutical innovations and overall medical progress. Experts argue that while initial returns on research funding may take time, the long-term benefits are invaluable.
Fundamental research is kind of the pacesetter of technical progress, as shown by the substantial impact NIH-funded studies have on pharmaceutical innovation.
When we invest in NIH-funded research, we get significant returns spread over many years, showcasing the importance of long-term funding for medical advances.
Collection
[
|
...
]